☆ 4.3 Article

Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications-A pilot study

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity

Tanaya Shree et al.

Summary: In patients with lymphoma, the time since anti-CD20 treatment is an important predictor of neutralizing antibody response to COVID-19 vaccination. Comparing patients who received anti-CD20 treatment before or after vaccination, we demonstrate that vaccinating first can generate a durable antibody response that persists during anti-CD20-containing treatment.

BLOOD CANCER DISCOVERY (2022)

Add to Collection

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis

Frederik Novak et al.

Summary: The study revealed a decreased humoral response after BNT162b2 mRNA SARS-CoV-2 vaccine in multiple sclerosis patients receiving B-cell depleting therapy, with some patients having insufficient antibody levels. Clinicians should advise patients treated with anti-CD20 to avoid exposure to SARS-CoV-2. Future research should investigate the impact of a third booster vaccine for patients with low or absent antibody levels after vaccination.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Medicine, General & Internal

Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy

Sachin P. Gadani et al.

Summary: This study found robust T cell responses in individuals with multiple sclerosis on anti-CD20 therapies despite a reduced humoral response to SARS-CoV-2 vaccination. Follow-up studies are needed to determine if this translates to protection against COVID-19 infection.

EBIOMEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy

Tobias Moser et al.

Summary: The study found that CLAD treatment does not interfere with patients' pre-existing specific antibody levels against pathogens, with seroprotection loss rate below 1%. There was no significant change in serum IgG levels under CLAD treatment, while absolute lymphocyte counts were significantly reduced at the end of each treatment year.

BIOMEDICINES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses

F. Javier Ibarrondo et al.

Summary: Studies on two SARS-CoV-2 mRNA vaccines have shown that they provide about 95% protection from symptomatic infection in the short term, but questions remain about the comparison and stability of vaccine-induced antibody levels to natural infection. Antibody levels decline similarly after vaccination and natural infection, indicating potential need for booster shots.

ACS NANO (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Sokratis A. Apostolidis et al.

Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.

NATURE MEDICINE (2021)

Add to Collection

Review Immunology

The role of TH17 cells in multiple sclerosis: Therapeutic implications

Tobias Moser et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Review Clinical Neurology

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis

David Baker et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Tobias Moser et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

S. L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Review Medicine, General & Internal

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

David Baker et al.

EBIOMEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

Ludwig Kappos et al.

LANCET (2011)

Add to Collection

Review Pharmacology & Pharmacy

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

Mohammad Tabrizi et al.

AAPS JOURNAL (2010)

Add to Collection

Article Immunology

Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice

David J. DiLillo et al.

JOURNAL OF IMMUNOLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.